South Korea Suspends Sales Of Pfizer Antibiotic For Labeling Problems
This article was originally published in PharmAsia News
Executive Summary
South Korea's Ministry of Food and Drug Safety ordered Pfizer's Zithromax (azithromycin) antibiotic suspended from the market for three months on grounds the drug label contained inaccurate information.
You may also be interested in...
Bristol’s CAR-T Strategy Comes Into Focus With Two Near-Term Filings
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
US FDA's Pediatric Experts, Not Review Division, Should Have Final Say On Pediatric Trials, Former Official Says
Former Associate Commissioner Janice Soreth says views of pediatric experts should take precedence over those of division directors regarding pediatric trials.
US FDA's Office Of New Drug Leaders Listen To Stakeholders
Twenty-five officials of FDA's Office of New Drugs gather to hear recommendations from stakeholders on what they can do to improve drug development programs.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports